SUPERNUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 933.39 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 41.00K shares, a 71.23% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 892.39K shares, a 15.60% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 110.30K shares, a 213.35% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 20.43K shares.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.21M shares, a 0.43% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.21M shares, a 0.18% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.20M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 41.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 933.39K shares 10-Q · filed 2026-08-03 | 1.04M shares derived: sum of 3 quarters · filed 2026-08-03 | 1.06M shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 892.39K shares 10-Q · filed 2026-05-05 | 1.00M shares derived: sum of 2 quarters · filed 2026-05-05 | 1.02M shares derived: sum of 3 quarters · filed 2026-05-05 | 1.05M shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 110.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 130.72K shares derived: sum of 2 quarters · filed 2026-03-02 | 154.67K shares derived: sum of 3 quarters · filed 2026-03-02 | 1.21M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 20.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 44.37K shares derived: sum of 2 quarters · filed 2025-11-06 | 1.10M shares 10-Q · filed 2025-11-06 | 1.14M shares derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | 23.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 1.08M shares 10-Q · filed 2025-08-05 | 1.12M shares derived: sum of 3 quarters · filed 2026-03-02 | |
| 2025-03-31 | 1.06M shares 10-Q · filed 2025-05-06 | 1.09M shares derived: sum of 2 quarters · filed 2026-03-02 | ||
| 2024-12-31 | 35.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 1.21M shares 10-K · filed 2026-03-02 | ||
| 2024-09-30 | 1.17M shares 10-Q · filed 2024-11-04 | |||
| 2023-12-31 | 1.20M shares 10-K · filed 2025-02-25 | |||
| 2013-09-30 | 951.08K shares 10-Q · filed 2013-11-13 | |||
| 2013-06-30 | 899.83M shares 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |